Business Context and Reporting Period
This Form 6-K filing by Novo Nordisk A/S, dated December 2, 2024, reports on the company's ongoing share repurchase programme. Novo Nordisk is a leading global healthcare company headquartered in Denmark, employing approximately 72,000 people across 80 countries. The filing details transactions executed under a specific sub-programme initiated on November 11, 2024, which is part of a broader 12-month repurchase plan authorized to begin on February 6, 2024.
Key Financial Metrics
The filing focuses on capital allocation via share buybacks rather than operational financial performance metrics such as revenue or profit.
- Total Repurchase Programme Cap: Up to DKK 20 billion.
- Current Sub-Programme Cap (Nov 11, 2024 - Feb 3, 2025): Up to DKK 3,136,206,122.30.
- Accumulated Repurchases (Since Feb 6, 2024): 21,427,104 B shares.
- Total Transaction Value (Since Feb 6, 2024): DKK 17,769,219,844.
- Average Share Price (Since Feb 6, 2024): DKK 829.29 per B share.
- Treasury Shares Held: 22,571,662 B shares (0.5% of share capital).
- Total Share Capital: 4,465,000,000 A and B shares (including treasury shares).
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Recent Transactions
Since the last announcement on November 25, 2024, the company executed the following transactions under the November 11, 2024 programme:
| Date | Number of B Shares | Average Purchase Price (DKK) | Transaction Value (DKK) |
|---|---|---|---|
| 25 November 2024 | 79,943 | 750.50 | 59,997,619 |
| 26 November 2024 | 80,000 | 754.08 | 60,326,499 |
| 27 November 2024 | 80,000 | 747.49 | 59,799,251 |
| 28 November 2024 | 72,075 | 748.28 | 53,932,072 |
| 29 November 2024 | 80,000 | 746.83 | 59,746,099 |
Accumulated transactions under this specific sub-programme total 1,224,005 shares with a value of DKK 905,425,967.
Guidance, Outlook, and Risks
Outlook: Novo Nordisk expects to continue repurchasing B shares up to the total programme limit of DKK 20 billion during the 12-month period beginning February 6, 2024. As of November 29, 2024, the company has utilized approximately DKK 17.77 billion of this authorization.
Regulatory Context: The repurchases are conducted in accordance with Article 5 of Regulation No 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 (Safe Harbour Rules).
Risks and Contingencies: The filing does not explicitly detail new risks or contingencies beyond the standard execution of the buyback programme.
Key Facts for Investor Verification
- Verify the remaining authorization under the DKK 20 billion programme (approximately DKK 2.23 billion remaining as of Nov 29, 2024).
- Confirm the current market price of B shares relative to the recent average purchase prices (ranging from DKK 746.83 to DKK 754.08 in late November).
- Monitor the total treasury share count, which currently represents 0.5% of the total share capital.
- Check the company website (novonordisk.com) for daily transaction details as required by the Safe Harbour Rules.